Canada's Cannabis Market So Far

Episode Summary

Executive Summary: The episode revisits Canada’s first months of recreational cannabis legalization with analyst Craig Wiggins, who argues rollout has been messy, supply constrained, and uneven across provinces. He says quality, genetics, taxation, and provincial distribution models are driving short-term losses, even as some premium brands and wholesale activity show promise. Investors are urged to focus on fundamentals: sales growth, gross margin, and operating leverage.

Main Topics: Canada’s chaotic recreational cannabis rollout (Priority: 5/5): Wiggins describes the national launch as a patchwork of provincial models with frequent shortages, poor coordination, and inconsistent retail availability. Supply constraints and production quality (Priority: 5/5): He argues many producers overpromised capacity, while weak genetics and greenhouse scaling problems led to mediocre flower and inventory shortages. Brand differentiation in cannabis (Priority: 4/5): Consumers are experimenting across brands and price points, but premium names with strong quality are gaining traction and social media attention. Financial metrics investors should watch (Priority: 5/5): The conversation focuses on sales growth, gross margin, SG&A, and EBITDA as the key indicators of whether cannabis firms can become viable businesses. Government taxation and provincial middlemen (Priority: 5/5): Both federal and provincial governments take a large cut and often add little operational value, raising costs and complicating the market structure. Medical vs. recreational market dynamics (Priority: 3/5): Medical demand has remained relatively stable in many cases, but government excise taxes on medical cannabis blur the distinction between medical and recreational use.

Key Arguments: The rollout was poorly executed, with provinces applying different wholesale/retail models and several jurisdictions suffering shortages. Licensed producers promised more than they could deliver, especially on funded capacity and consistent supply. Cannabis quality depends heavily on genetics and controlled growing conditions; scaling greenhouse production takes time to optimize. Premium brands can command higher prices and build loyalty, but mass-market products are still in a trial-and-error phase. Gross margin is the central profitability metric; high revenue alone does not matter if production and operating expenses remain too high. Investors should look for inflection points in SG&A and EBITDA rather than assume growth alone will eventually solve the business model. Government excise taxes and provincial distribution structures materially compress industry economics. Medical cannabis remains a real use case, and treating it as merely disguised recreation is overly simplistic.

Data Points: Number of provinces with wholesaler role: 9 of 10 major provinces - Wiggins says most provinces chose to act as wholesalers in the recreational cannabis system. Current legal cannabis form factors in Canada: 2 - At the time, only flower and oil were legal recreational formats. Expected new legal form factors: October of that year - Edibles/form factor 2.0 were expected after the discussion period ended. Publicly traded cannabis companies in Canada: north of 50 - Wiggins estimates there were more than 50 publicly traded names in the sector. Cannabis licenses in Canada: 140–150 - He estimates the number of licenses in the market. Broken Coast price premium: + $10 per gram - Premium flower brands were selling at a higher retail price than legacy-market cannabis. Canopy Growth gross margin: 22% - He cites Canopy’s last-quarter gross margin as evidence of weak profitability. Canopy Growth prior gross margin: 28% - He says Canopy’s gross margin fell from 28% to 22%. Aurora gross margin: 54% - He notes Aurora’s margin also declined somewhat. Canopy net revenue: $83 million - Last quarter net revenue cited, net of excise tax. Canopy OpEx: $170 million - Operating expenses were far above revenue. Aurora OpEx vs sales: over 200% of sales - Used to illustrate how costs can exceed revenue by a wide margin. Aurora adjusted EBITDA: approximately -$33 million - Wiggins’s estimate of Aurora’s adjusted EBITDA at the time. Canopy SG&A/OpEx to sales: 700% to 200% - He says Canopy improved dramatically from around 700% down to 200%. Excise/tax take: 40%–50% of net purchase price - Combined federal and provincial taxes were estimated to consume nearly half the purchase price. Ontario retail license lottery fee: $75 - Applicants entered a lottery for retail licenses at minimal cost. Ontario retail licenses in lottery: 25 - The province planned to issue 25 licenses through the lottery system.

Pivotal Quotes: "the term gong show would probably be apropos for how adult rec has been rolled out throughout Canada." — Craig Wiggins: His blunt assessment of the early recreational cannabis rollout in Canada. "I care about the steak, not the sizzle, so much." — Craig Wiggins: He explains his preference for fundamentals over hype when evaluating cannabis stocks. "Between the federal and the provincial taxes, I think they're taking 40 to 50 percent of the net purchase price into taxes in one form or another" — Craig Wiggins: He describes how taxation is squeezing industry economics.

Implications: The sector’s winners will likely be companies that solve quality, scale, and unit economics—not just those with the most hype. Provincial policy and taxes remain major drag factors, so investors should watch margin improvement and real operating discipline.